Effect of Vitamin D3 on Vascular Function

Vitamin D Deficiency Clinical Trial

Official title:

The Effect of Cholecalciferol (Vitamin D3) on Vascular Function and Cardiovascular Risk Factors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00948298
• Other study ID #: IRB#08-05-2170-01
• Secondary ID: U54RR022762
• Status: Completed
• Phase: N/A
• Start date: July 2009
• Est. completion date: August 2012

Study information

• Verified date: June 2018
• Source: Charles Drew University of Medicine and Science
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vitamin D is a natural nutrient. A little comes from our normal daily diet. Most of it comes from our skin after we have been in sunlight. If we have darker skin, we make less vitamin D. Vitamin D balances the calcium in our body. If our vitamin D levels get too low, it can cause health problems. It may increase our chance of getting high blood pressure or diabetes. Another problem we may have if our vitamin D levels are low is that our blood vessels may not work normally. These are important health problems for anyone. Because African Americans have darker skin, they are more likely than most other racial/ethnic groups to have low vitamin D levels. This study will look at treating African Americans with low vitamin D levels.

The goal of this study is to see how vitamin D helps blood vessels work. The investigators will do this study in African Americans who are overweight, have high blood pressure and have low vitamin D levels. The investigators will see if getting the vitamin D level to a normal value will improve how blood vessels work. The dose of vitamin D that will be given in this study is a high dose that is given to people with low vitamin D levels.

Description:

Cardiovascular Disease (CVD) and related disorders remain the leading cause of death in the nation. Hypovitaminosis D has been linked not only to several cardiovascular (CV) risk factors including hypertension, diabetes, obesity but also to increased rates of CVD. Thus,hypovitaminosis D presents a common pathway for a select subgroup with a clustering of CV risk factors in a profile that is predominant among ethnic minorities. Indeed, hypovitaminosis D is highly prevalent with an estimated 55% of the US adult population having levels at or below 30 ng/ml, and over 80% of African Americans having suboptimal values. Thus, we propose a twelve week randomized double-blind, placebo controlled pilot trial to assess the effect on vascular function and CV risk factors of 100,000 IU Vitamin D3 given every 4 weeks to overweight, hypertensive African-Americans with hypovitaminosis D. To our knowledge, the proposed project is the first to assess the effect of 'high-dose' Vitamin D3 administration on vascular function.We believe this study is also the first to examine the impact at a molecular level of Vitamin D3 repletion on the key mediators of cardio-metabolic pathways in humans. If our study results support our working hypothesis, we will be positioned to propose a larger scale study to detect a therapeutic effect on more definitive, clinical cardiovascular endpoints across a more diverse population.

Objectives:

1. Assess the role of Vitamin D3 treatment on vascular function in high risk subjects.

Primary Outcome: The primary outcome variable is pulse wave velocity (PWV, unit - m/s) for vascular stiffness assessed by radial artery tonometry (via SphygmoCor). The hypothesis for the primary analysis is that a greater increase in the PWV will occur in the Vitamin D3 treatment group than in the placebo group.

Secondary Outcome: Vascular/endothelial function as determined by measuring non-invasive vascular finger plethysmography (via EndoPat). Additional surrogates to be assessed as secondary markers of vascular/endothelial function include sitting and 24 hour ambulatory blood pressure measurements and spot urine protein/creatinine ratio.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: August 2012
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Males or females, 18-70 years of age and self-identified as African-American or Black

• Hypertension

• If a potential study patient is not on treatment, their systolic blood pressure (SBP) must be > 130 mmHg, or diastolic blood pressure (DBP) > 85 mmHg, and SBP must be <160 mmHg and DBP must be < 105 mmHg.

• If a potential study patient is on treatment then the SBP must be <160 mmHg and DBP must be < 105 mmHg

• Screening Vitamin D (D2 and D3 level) between 10 and 25 ng/ml (normal level > 30 ng/ml)

• Body mass index (BMI) > 25 kg/m2

Exclusion Criteria:

• Poorly controlled high blood pressure (SBP >160 mmHg or DBP > 105 mmHg)

• Diabetes (fasting blood sugar > 125 mg/dl, or HbA1c > 6.5%)

• Screening Vitamin D (D2 and D3 level) < 10 ng/ml or > 25 ng/ml

• Estimated glomerular filtration rate (eGFR) < 45 ml/min

• Evidence of disease resulting in hypercalcemia

• History of kidney stones

• History of drug, alcohol, or illicit substance abuse within the past 6 months

• History of another chronic disease which the investigator feels should preclude the subject from entering the study

• Liver function tests (LFTs) greater than twice the upper limit of normal

• Subjects requiring chronic use of nonsteroidal anti-inflammatory drugs, aspirin, or other drugs that may affect the measurement of reactive oxidative species

• Subjects requiring treatment with other vitamin D preparations containing more than 400 IU of vitamin D

• Subjects requiring chronic use of immunosuppressive therapy or corticosteroids

• Recent (< 6 months) myocardial infarction, stroke, or hospitalization for congestive heart failure

• Allergy/intolerance: known allergy to oral vitamin D or microcrystalline cellulose

Related Conditions & MeSH terms

• Vitamin D Deficiency

Intervention

Drug:
• Vitamin D
Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
• Placebo
Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Charles Drew University of Medicine and Science	National Center for Research Resources (NCRR)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulse Wave Velocity for Vascular Stiffness	The primary outcome variable is pulse wave velocity (PWV) for vascular stiffness. The hypothesis is that a greater decrease in the PWV will occur with the Vitamin D3 treatment. PWV is the speed at which the arterial pulse wave travels through the arteries in the cardiovascular system. It is considered the gold standard for the assessment of arterial elastance (stiffness) and determined by radial artery applanation tonometry using the SphygmoCor device.	12 Weeks
Secondary	Changes in Sitting and 24 Ambulatory Blood Pressure	Improved vascular function as determined by measuring sitting and 24 Hour Ambulatory Blood Pressure.	12 weeks